Latest Spongiform Encephalopathy Companies Update
Roche Diagnostics Developed a new blood test for detecting misfolded prion proteins, offering a potentially less invasive and more accessible approach to CJD diagnosis compared to traditional brain biopsies.
Mayo Clinic Implemented advanced MRI techniques with improved sensitivity for identifying early brain changes associated with CJD, potentially enabling earlier diagnosis and intervention.
Quanterix Corporation Received FDA approval for its Simoa™ prion protein assay, a highly sensitive blood test for CJD, advancing potential for earlier detection and disease monitoring.
Denali Therapeutics Initiated Phase 2 clinical trials for its investigational drug DNL310, targeting the accumulation of misfolded prion proteins in CJD, holding promise for disease modification.
Currie Therapeutics Developed a potential gene therapy approach for GSS, currently in preclinical stages, aiming to address the underlying genetic cause of the disease.
List of Spongiform Encephalopathy Key Companies in the Market
- Teva Pharmaceuticals
- Abbvie
- Adamas Pharmaceuticals Inc.
- Newron Pharmaceuticals SPA
- Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Lonza
- Merck KGaA
- Thermo Fisher Scientific Inc
